Dalia Waldman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dalia Waldman has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Amos Toren
2 shared publicationsAbdalla Khalil
1 shared publication- Abraham Kuten
Oncology Institute, Rambam Health Care Campus, P.O. Box 9602, Haifa 31096, Israel
1 shared publication - Aharon Lubetsky
National Hemophilia Center, Sheba Medical Center, Ramat-Gan 5266202, Israel
1 shared publication - Alexander Nevelsky
Division of Oncology Rambam Health Care Campus Haifa Israel
1 shared publication Alison Berniger
1 shared publication
Latest Publications
- 1 January 2013
- Vol. 15 (1) , 31-4
Targeted therapy with low doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Palliative treatment ore remains a significant clinical problem. To retrospectively determine the clinical response to 131I-MIBG therapy at low doses in patients with refractory neuroblastoma. We performed a retrospective chart review of 10 patients with neuroblastoma treated with 1311-MIBG at Rambam Health Care Campus from 1994 to 2012. Clinical data, number of 131I-MIBG courses delivered, toxicities, and clinical responses were reviewed. MIBG scan was performed after each course. Twenty-one courses of 131I-MIBG were delivered to 10 patients (3 girls, 7 boys). Their mean age was 3.8 years (range 1.5-6 years). All patients received several protocols of chemotherapy including the high dose form. Three patients received three courses of 131I-MIBG with a minimum of 6 weeks between each course, five patients received two courses, and two patients received only one course. An objective response to the first course was obtained in nine patients and to the second course in six of eight, and in three children who underwent the third course the pain decreased. One patient has no evidence of disease, four are alive with disease, and five died of the disease. No unanticipated toxicities were observed. Low dose 131I-MIBG is an effective and relatively non-toxic treatment in neuroblastoma disease palliation. Rapid and reproducible pain relief with 131I-MIBG was obtained in most of the children. Treatment with systemic radiotherapy in the form of low dose 131I-MIBG was easy to perform and effective in cases of disseminated neuroblastoma, demonstrating that this primary therapy can be used for palliative purposes.
- 1 January 2013
- Vol. 15 (1) , 31-4
Targeted therapy with low doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Palliative treatment ore remains a significant clinical problem. To retrospectively determine the clinical response to 131I-MIBG therapy at low doses in patients with refractory neuroblastoma. We performed a retrospective chart review of 10 patients with neuroblastoma treated with 1311-MIBG at Rambam Health Care Campus from 1994 to 2012. Clinical data, number of 131I-MIBG courses delivered, toxicities, and clinical responses were reviewed. MIBG scan was performed after each course. Twenty-one courses of 131I-MIBG were delivered to 10 patients (3 girls, 7 boys). Their mean age was 3.8 years (range 1.5-6 years). All patients received several protocols of chemotherapy including the high dose form. Three patients received three courses of 131I-MIBG with a minimum of 6 weeks between each course, five patients received two courses, and two patients received only one course. An objective response to the first course was obtained in nine patients and to the second course in six of eight, and in three children who underwent the third course the pain decreased. One patient has no evidence of disease, four are alive with disease, and five died of the disease. No unanticipated toxicities were observed. Low dose 131I-MIBG is an effective and relatively non-toxic treatment in neuroblastoma disease palliation. Rapid and reproducible pain relief with 131I-MIBG was obtained in most of the children. Treatment with systemic radiotherapy in the form of low dose 131I-MIBG was easy to perform and effective in cases of disseminated neuroblastoma, demonstrating that this primary therapy can be used for palliative purposes.
- 25 March 2004
- Published by Wiley in American Journal of Hematology
- Vol. 75 (4) , 217-219
Favorable early response of secondary chronic myeloid leukemia to imatinib
Second malignant neoplasms are gradually becoming a recognized long‐term complication of successful cancer treatment, and they usually respond poorly to conventional therapy and have an unfavorable outcome. Chronic myeloid leukemia (CML) is a clonal panmyelopathy, rarely seen in children with a specific cytogenetic aberration—the Philadelphia chromosome. The translocation generates an aberrant tyrosine kinase, which drives the malignant process in CML and which is also the molecular target for successful treatment of CML with imatinib. It is also exceedingly rare as a secondary malignant neoplasm in both adults and children. We report two cases of secondary CML. The first occurred after successful treatment for nasopharyngeal carcinoma in a child, and the second after treatment for lymphoma in an adolescent. Both patients had an excellent response to treatment with imatinib and attained complete cytogenetic remissions. We conclude that secondary CML may respond favorably to treatment with imatinib. Am. J. Hematol. 75:217–219, 2004.
- 25 March 2004
- Published by Wiley in American Journal of Hematology
- Vol. 75 (4) , 217-219
Favorable early response of secondary chronic myeloid leukemia to imatinib
Second malignant neoplasms are gradually becoming a recognized long‐term complication of successful cancer treatment, and they usually respond poorly to conventional therapy and have an unfavorable outcome. Chronic myeloid leukemia (CML) is a clonal panmyelopathy, rarely seen in children with a specific cytogenetic aberration—the Philadelphia chromosome. The translocation generates an aberrant tyrosine kinase, which drives the malignant process in CML and which is also the molecular target for successful treatment of CML with imatinib. It is also exceedingly rare as a secondary malignant neoplasm in both adults and children. We report two cases of secondary CML. The first occurred after successful treatment for nasopharyngeal carcinoma in a child, and the second after treatment for lymphoma in an adolescent. Both patients had an excellent response to treatment with imatinib and attained complete cytogenetic remissions. We conclude that secondary CML may respond favorably to treatment with imatinib. Am. J. Hematol. 75:217–219, 2004.
- 1 January 2004
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 92 (10) , 713-718
Paediatric cerebral sinus vein thrombosis
Schattauer GmbH - Verlag für Medizin und Naturwissenschaften ist ein renommierter Herausgeber von Fachbüchern, -zeitschriften und -software. Besuchen Sie unser Internetangebot mit Onlinezugang zu unseren Zeitschriftenartikeln
- 1 January 2004
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 92 (10) , 713-718
Paediatric cerebral sinus vein thrombosis
Schattauer GmbH - Verlag für Medizin und Naturwissenschaften ist ein renommierter Herausgeber von Fachbüchern, -zeitschriften und -software. Besuchen Sie unser Internetangebot mit Onlinezugang zu unseren Zeitschriftenartikeln